Brentuximab Vedotin and CHP as Front-Line Therapy in ALCL and NK/T-Cell Lymphomas


Brentuximab Vedotin and CHP as Front-Line Therapy in ALCL and NK/T-Cell Lymphomas
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Brad S Kahl, MD (1/17/13)

Fanale MA et al. Brentuximab vedotin administered concurrently with multi-agent chemotherapy as frontline treatment of ALCL and other CD30-positive mature T cell and NΚ cell lymphomas. Proc ASH 2012;Abstract 60.

Dr Kahl is Skoronski Chair of Lymphoma Research and Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at UW Carbone Cancer Center in Madison, Wisconsin.